Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy – appraisal consultation document

In this DRAFT guidance, carfilzomib with lenalidomide and dexamethasone is not recommended for previously treated multiple myeloma in adults due to uncertainty about how long the benefit lasts after stopping treatment and uncertain of cost-effectiveness estimates.

National Institute for Health and Care Excellence